Quest Diagnostics has patented a method for detecting mutant nucleic acid sequences associated with cancer using primer directed amplification and nucleic acid fragmentation. The kit includes oligonucleotide primers and restriction enzymes, offering high sensitivity even in the presence of non-target nucleic acids. GlobalData’s report on Quest Diagnostics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Quest Diagnostics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Quest Diagnostics, was a key innovation area identified from patents. Quest Diagnostics's grant share as of April 2024 was 55%. Grant share is based on the ratio of number of grants to total number of patents.

Kit for detecting mutant nucleic acid sequence associated with cancer

Source: United States Patent and Trademark Office (USPTO). Credit: Quest Diagnostics Inc

A recently granted patent (Publication Number: US11965212B2) discloses a kit designed for detecting mutant nucleic acid sequences associated with cancer. The kit includes oligonucleotide primer pairs and restriction enzymes, with the primers specifically targeting fragmentation sites absent in mutant sequences. Notably, the oligonucleotide primers are labeled with detectable moieties, such as fluorescent dyes, to enable visual identification of mutations.

Furthermore, the kit offers versatility by allowing different primer pairs to be labeled with distinct moieties, enhancing the detection process. The patent specifies that the mutant nucleic acid sequences may contain various mutations like insertions, deletions, substitutions, or translocations compared to wild-type sequences. Additionally, the kit targets a range of cancers including non-small cell lung cancer, breast cancer, colon cancer, ovarian cancer, hepatocellular cancer, and pancreatic cancer, broadening its applicability in cancer detection and research. The use of specific restriction enzymes like MnlI, MseI, EaeI, FatI, and HpyCH4VI further enhances the precision and accuracy of the detection process outlined in the patent.

To know more about GlobalData’s detailed insights on Quest Diagnostics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.